The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial

ABSTRACT: The Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and prov...

Full description

Autores:
Rios Romenets, Silvia
Giraldo Chica, Margarita María
López, H.
Piedrahita, F.
Ramos, Claudia Patricia
Acosta Baena, Natalia
Muñoz, C.
Ospina, P.
Tobón Quintero, Carlos Andrés
Cho, William
Ward, M.
Langbaum, Jessica
Tariot, Pierre
Reiman, Eric M.
Lopera Restrepo, Francisco Javier
Tipo de recurso:
Article of investigation
Fecha de publicación:
2018
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/23012
Acceso en línea:
http://hdl.handle.net/10495/23012
Palabra clave:
Enfermedad de Alzheimer
Alzheimer Disease
Prevención de Enfermedades
Disease Prevention
Registros
Records
Autosomal dominant Alzheimer’s disease
Alzheimer’s prevention initiative
Registry
Pre- screening
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/
id UDEA2_d5c5c85cb6d1d6062818fc98c288adf0
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/23012
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
title The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
spellingShingle The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
Enfermedad de Alzheimer
Alzheimer Disease
Prevención de Enfermedades
Disease Prevention
Registros
Records
Autosomal dominant Alzheimer’s disease
Alzheimer’s prevention initiative
Registry
Pre- screening
title_short The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
title_full The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
title_fullStr The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
title_full_unstemmed The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
title_sort The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
dc.creator.fl_str_mv Rios Romenets, Silvia
Giraldo Chica, Margarita María
López, H.
Piedrahita, F.
Ramos, Claudia Patricia
Acosta Baena, Natalia
Muñoz, C.
Ospina, P.
Tobón Quintero, Carlos Andrés
Cho, William
Ward, M.
Langbaum, Jessica
Tariot, Pierre
Reiman, Eric M.
Lopera Restrepo, Francisco Javier
dc.contributor.author.none.fl_str_mv Rios Romenets, Silvia
Giraldo Chica, Margarita María
López, H.
Piedrahita, F.
Ramos, Claudia Patricia
Acosta Baena, Natalia
Muñoz, C.
Ospina, P.
Tobón Quintero, Carlos Andrés
Cho, William
Ward, M.
Langbaum, Jessica
Tariot, Pierre
Reiman, Eric M.
Lopera Restrepo, Francisco Javier
dc.subject.decs.none.fl_str_mv Enfermedad de Alzheimer
Alzheimer Disease
Prevención de Enfermedades
Disease Prevention
Registros
Records
topic Enfermedad de Alzheimer
Alzheimer Disease
Prevención de Enfermedades
Disease Prevention
Registros
Records
Autosomal dominant Alzheimer’s disease
Alzheimer’s prevention initiative
Registry
Pre- screening
dc.subject.proposal.spa.fl_str_mv Autosomal dominant Alzheimer’s disease
Alzheimer’s prevention initiative
Registry
Pre- screening
description ABSTRACT: The Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test of the amyloid hypothesis. The Neurosciences Group of Antioquia implemented a pre-screening process with the goals of decreasing screen failures and identifying participants most likely to adhere to trial requirements of the API ADAD trial in cognitively unimpaired members of Presenilin1 E280A mutation kindreds. The pre-screening failure rate was 48.2%: the primary reason was expected inability to comply with the protocol, chiefly due to work requirements. More carriers compared to non-carriers, and more males compared to females, failed pre-screening. Carriers with illiteracy or learning/comprehension difficulties failed pre-screening more than non-carriers. With the Colombian API Registry and our prescreening efforts, we randomized 169 30-60 year-old cognitively unimpaired carriers and 83 non-carriers who agreed to participate in the trial for at least 60 months. Our findings suggest multiple benefits of implementing a pre-screening process for enrolling prevention trials in ADAD.
publishDate 2018
dc.date.issued.none.fl_str_mv 2018
dc.date.accessioned.none.fl_str_mv 2021-10-08T02:58:35Z
dc.date.available.none.fl_str_mv 2021-10-08T02:58:35Z
dc.type.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.hasversion.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ART
dc.type.local.spa.fl_str_mv Artículo de investigación
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.issn.none.fl_str_mv 2090-8024
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10495/23012
dc.identifier.doi.none.fl_str_mv 10.14283/jpad.2017.44.
dc.identifier.eissn.none.fl_str_mv 2090-0252
identifier_str_mv 2090-8024
10.14283/jpad.2017.44.
2090-0252
url http://hdl.handle.net/10495/23012
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Int. J. Alzheimers. Dis.
dc.rights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/2.5/co/
dc.rights.accessrights.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.spa.fl_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/2.5/co/
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.format.extent.spa.fl_str_mv 11
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Hindawi
dc.publisher.group.spa.fl_str_mv Grupo Neuropsicología y Conducta
dc.publisher.place.spa.fl_str_mv Nueva York, Estados Unidos
institution Universidad de Antioquia
bitstream.url.fl_str_mv http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/1/GiraldoM_2018_ValuePre-ScreeningAlzheimers.pdf
http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/3/license.txt
http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/2/license_rdf
bitstream.checksum.fl_str_mv ed2439ec1cb6aa9088cacae7f0932998
8a4605be74aa9ea9d79846c1fba20a33
1646d1f6b96dbbbc38035efc9239ac9c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad de Antioquia
repository.mail.fl_str_mv andres.perez@udea.edu.co
_version_ 1812173078246981632
spelling Rios Romenets, SilviaGiraldo Chica, Margarita MaríaLópez, H.Piedrahita, F.Ramos, Claudia PatriciaAcosta Baena, NataliaMuñoz, C.Ospina, P.Tobón Quintero, Carlos AndrésCho, WilliamWard, M.Langbaum, JessicaTariot, PierreReiman, Eric M.Lopera Restrepo, Francisco Javier2021-10-08T02:58:35Z2021-10-08T02:58:35Z20182090-8024http://hdl.handle.net/10495/2301210.14283/jpad.2017.44.2090-0252ABSTRACT: The Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test of the amyloid hypothesis. The Neurosciences Group of Antioquia implemented a pre-screening process with the goals of decreasing screen failures and identifying participants most likely to adhere to trial requirements of the API ADAD trial in cognitively unimpaired members of Presenilin1 E280A mutation kindreds. The pre-screening failure rate was 48.2%: the primary reason was expected inability to comply with the protocol, chiefly due to work requirements. More carriers compared to non-carriers, and more males compared to females, failed pre-screening. Carriers with illiteracy or learning/comprehension difficulties failed pre-screening more than non-carriers. With the Colombian API Registry and our prescreening efforts, we randomized 169 30-60 year-old cognitively unimpaired carriers and 83 non-carriers who agreed to participate in the trial for at least 60 months. Our findings suggest multiple benefits of implementing a pre-screening process for enrolling prevention trials in ADAD.COL000755111application/pdfengHindawiGrupo Neuropsicología y ConductaNueva York, Estados Unidosinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTArtículo de investigaciónhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by/4.0/The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease TrialEnfermedad de AlzheimerAlzheimer DiseasePrevención de EnfermedadesDisease PreventionRegistrosRecordsAutosomal dominant Alzheimer’s diseaseAlzheimer’s prevention initiativeRegistryPre- screeningInt. J. Alzheimers. Dis.International Journal of Alzheimer's Disease495451ORIGINALGiraldoM_2018_ValuePre-ScreeningAlzheimers.pdfGiraldoM_2018_ValuePre-ScreeningAlzheimers.pdfArtículo de investigaciónapplication/pdf324897http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/1/GiraldoM_2018_ValuePre-ScreeningAlzheimers.pdfed2439ec1cb6aa9088cacae7f0932998MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/2/license_rdf1646d1f6b96dbbbc38035efc9239ac9cMD5210495/23012oai:bibliotecadigital.udea.edu.co:10495/230122021-10-07 21:58:35.633Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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